Canopus Biopharma In (CBIA) 0.1000 $CBIA Ebola Viral

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Canopus Biopharma In (CBIA) 0.1000 $CBIA

Ebola Viral Infections Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Dec 17, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zhmmv6/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Arno Therapeutics, Inc. - Canopus BioPharma Incorporated - Etubics Corporation - FIT Biotech Oy - Merck & Co., Inc. - Microbiotix, Inc. - Micropharm Limited - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxeal Holding SA - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/zh...bola_viral
UTHR: 121.81 (-2.77), MRK: 61.81 (-1.38)

Canopus BioPharma Inc. announces positive results from an In-Vitro live Ebola Virus study
PR Newswire Europe - Fri Dec 19, 8:00AM CST
Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 389

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 255

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 281

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 270

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 314

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 216

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 134

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 233

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading

Top 5 Most Recently Viewed Articles

Riliprubart's Orphan Drug Designation: A Path to Innovation

Updated Category News Views 190

Riliprubart's Orphan Drug Designation in Japan Riliprubart has been granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy (CIDP), a significant milestone in addressing an unmet medical need for many patients suffering from this rare neurological disorder. Key Highlights of the Designation This recognition from the Japanese Ministry...

Continue Reading
Harnessing the Future of Finance: IO DeFi's Sustainable Innovations

Updated Category News Views 268

Exploring the Impact of Digital Finance Innovations In an era where the financial landscape is rapidly transforming, the arrival of innovative platforms like IO DeFi highlights the transition toward more sustainable investment opportunities. As stakeholders worldwide keep a close watch on regulations shaping digital currencies, Europe is keen to develop its compliant...

Continue Reading
Rhino Introduces New Employment Protection Program for Renters

Updated Category News Views 1013

Rhino's Innovative Employment Protection for Renters The new program will provide renters with financial security and peace of mind in the case of an unexpected job loss. Rhino, a pioneer in security deposit insurance, has announced the introduction of 'Loss of Employment Protection,' specifically designed to assist renters who may face unexpected financial struggles due...

Continue Reading
Textron Reassesses Powersports Production in Market Shift

Updated Category News Views 162

Textron's Strategic Refocus on Powersports Textron Inc. has recently announced a significant strategic shift regarding its Powersports product line, indicating a response to sluggish consumer demand. This decision has resulted in a drop in shares as the company prepares for an indefinite production pause in the first half of 2025. Textron's leadership understands the...

Continue Reading
Exciting Announcements from JAMBALOO Music Festival

Updated Category News Views 167

Exciting Announcements from JAMBALOO Music Festival In a thrilling development for music lovers, the JAMBALOO Music Festival has unveiled its expanded artist lineup and a groundbreaking streaming partnership. The festival is set to captivate audiences with a week of live performances that will resonate across the nation. Streaming Partnership with WFAA+ The JAMBALOO Music...

Continue Reading